Rahman et al. Factors associated with fatigue and its improvement in trials IL23i guselkumab. Disease activity/function (34%), joints (16%), skin (12%) but 38.5% of fatigue variability remains unexplained. @RheumNow #EULAR2022 OP0025 https://t.co/C08R0IWM3S https://t.co/QnCvPwEwKS